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Potholes
DUI LAW IN THE BUDDING MARIJUANA INDUSTRY
INTRODUCTION
Few areas of public opinion and policy have changed as
rapidly in the past decade as those concerning the acceptable
use of marijuana. While the use of marijuana can be traced back
for millennia,1 Americans have only recently started accepting
the sanctioning of marijuana for medicinal or recreational
purposes.2 When Gallup began polling on marijuana legalization
in 1969, only 12% of Americans favored legalization.3 By the
start of the new millennium, that number had steadily risen to
about 30%.4 The last decade has seen a remarkable spurt in
public acceptance of marijuana legalization.5 As of this writing, a
historically high 60% of the nation now favors the legalization of
marijuana.6 A majority of states have laws permitting the use of
cannabis or its extracts for various medical purposes.7 Four
states and the District of Columbia have legalized recreational
use of marijuana, and many states are primed to follow in their
footsteps in the near future.8 Four additional states—California,
Maine, Massachusetts, and Nevada—approved recreational
1 Agata Blaszczak-Boxe, Marijuana’s History: How One Plant Spread Through
the World, LIVE SCI. (Oct. 17, 2014), http://www.livescience.com/48337-marijuana-historyhow-cannabis-travelled-world.html [https://perma.cc/CNE2-6UMA].
2 See, e.g., Christopher Ingraham, Gallup: Support for Legal Marijuana at
an All-time High and Likely to Grow, WASH. POST (Oct. 21, 2015), https://www.
washingtonpost.com/news/wonk/wp/2015/10/21/gallup-nearly-60-percent-of-americanswant-legal-marijuana [https://perma.cc/ZL5X-AL6R].
3 Art Swift, Support for Legal Marijuana Use Up to 60% in U.S., GALLUP (Oct.
19, 2016), http://www.gallup.com/poll/196550/support-legal-marijuana.aspx [https://perma.
cc/2564-BST3].
4 Id.
5 See id.
6 Id. (The polling isn’t clear as to whether the support is for recreational use
or simply medical use.).
7 Medical
Marijuana, NORML, http://norml.org/legal/medical-marijuana-2
[https://perma.cc/U7E6-UH86]. This includes states that permit the medical use of
cannabidiol (CBD) extracts. Id. CBD is the non-psychoactive compound found in
marijuana that has been used to treat various ailments, particularly seizure disorders.
What Is CBD?, PROJECT CBD, https://www.projectcbd.org/what-cbd [https://perma.cc/S
S39-C7CY].
8 See Ingraham, supra note 2.
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marijuana initiatives at the polls on November 8, 2016.9
Additional support exists at the federal level where progressive
lawmakers have pushed to end federal prohibition of the drug,10
thus opening the gate for states to create their own marijuana
policies free from federal interference.11 Given the trajectory of
marijuana legalization,12 the green rush has just started.13
The rapid legalization of marijuana across the country
will inevitably create new and unique legal issues for lawmakers
in a non-prohibitionist regime. Perhaps the most idiosyncratic
and problematic issue associated with the increase in legal
marijuana is the manner in which states will regulate its use by
drivers on the nation’s highways and roads. While many states
have legalized the medical or recreational use of marijuana, they
have had trouble establishing clear, scientifically legitimate, and
penologically appropriate laws regarding drivers who use
marijuana legally. Instead, having pushed marijuana as a drug
similar to alcohol for political purposes to gain support for
legalization,14 policymakers are now increasingly looking at
alcohol DWI laws as a basis for marijuana DUI laws.15 While
analogizing the effects of marijuana to those of alcohol for the
purpose of gaining public support is politically expedient, such
a comparison lacks any scientific legitimacy.
9 Melia Robinson & Skye Gould, This Map Shows Every State that Legalized
Marijuana on Election Day, BUSINESS INSIDER (Nov. 9, 2016), http://www.businessinsider.
com/where-is-marijuana-legal-2016-11 [https://perma.cc/8AVG-FBXP].
10 Marijuana remains a Schedule I drug under federal law. Schedule I drugs are
defined as drugs that have a high potential for abuse, no accepted medical use, and are
unsafe. 21 U.S.C. § 812 (2012). The federal government has stubbornly refused to
reschedule marijuana to reflect its medicinal benefits. See Jay M. Tiftickjian, A Brief History
of Marijuana Legislation in Colorado, in MEDICOLEGAL ASPECTS OF MARIJUANA: COLORADO
EDITION 2 (Jay M. Tiftickjian ed., 2015) [hereinafter Tiftickjian, History of Marijuana
Legislation in Colorado]. This is merely another example of how both federal and state
governments have been slow to adapt marijuana laws to reflect scientific realities.
11 See Ingraham, supra note 2.
12 See id.
13 See Tom Huddleston, Jr., Legal Marijuana Sales Could Hit $6.7 Billion In
2016, FORBES (Feb. 1, 2016), http://fortune.com/2016/02/01/marijuana-sales-legal/ [https://
perma.cc/TG3R-5AA2].
14 Legalization advocates have drawn parallels between the current regulation of
alcohol and the potential regulation of marijuana. It seems likely that such a comparison
makes legalization efforts more palatable to voters. This is evidenced by the Marijuana
Policy Project’s various statewide legalization campaigns, entitled: “Regulate Marijuana
Like Alcohol.” See Ballot Initiative Campaigns, MARIJUANA POLICY PROJECT, https://
www.mpp.org/about/campaigns [https://perma.cc/98SF-T9T8].
15 It should be noted that states vary widely amongst each other with regard to
the statutory language they use for various driving offenses involving alcohol and other
drugs. States have charges for DUI (driving under the influence), DWAI (driving while
ability impaired), and DWI (driving while intoxicated), etc. As it pertains to this note,
these distinctions are not particularly relevant. Compare N.Y. VEH. & TRAF. LAW § 1192
(McKinney 2016) (containing both a DWAI and DWI law), with COLO. REV. STAT. § 42-41301 (2016) (containing both a DUI law and DWAI law).
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Marijuana is distinctive from a drug like alcohol, which
is easy to test for and metabolizes in the human body at a
similar rate among all individuals.16 Marijuana is highly
unique in that it metabolizes at different rates among different
individuals depending upon a variety of factors and can typically
only be accurately tested with a blood sample.17 Most importantly,
marijuana compounds can stay in the human body after weeks of
abstinence depending on individual factors such as frequency of
use.18 These idiosyncrasies necessarily make legal marijuana
patients, and those who are chronic recreational users, especially
susceptible to DUI prosecution in states that have created
threshold amounts for marijuana in the blood system—similar to
the blood-alcohol-content (BAC) used for DWI convictions. The
increasing number of states legalizing marijuana usage will only
exacerbate this growing problem until jurisdictions make certain
policy and statutory changes. Without such changes, legal
marijuana users will be stuck navigating through the weeds of
irrational DUI laws.
This note examines the science behind marijuanaimpaired driving before analyzing various states’ marijuana DUI
laws. Part I of this note examines the unique scientific properties
of marijuana and its impairing effects as compared to alcohol’s
intoxicating properties. This part also illustrates the chemical
characteristics of marijuana that make it difficult to create
numerical thresholds (like a .08 BAC for alcohol), which correlate
with driving impairment. Part II provides a comparative analysis
of selected states—Arizona, Colorado, and New York—with either
medical or recreational marijuana regimes, and the ways in
which they have managed the issue of marijuana DUIs. Part III
uses New York’s current DUI laws as the foundation upon which
to recommend various statutory and policy changes, with the goal
of creating a marijuana DUI regime based, more compellingly, on
science, impairment, and dangerousness. This note argues that
reliance on statutory numerical thresholds is illogical given
marijuana’s unique scientific properties; instead, states should
adopt a more subjective approach to enforcing such laws by
relying upon drug recognition experts (DREs)19 in conjunction
with body-cameras to achieve DUI prosecutions.
16 See Andrea Roth, The Uneasy Case for Marijuana as Chemical Impairment
Under a Science-Based Jurisprudence of Dangerousness, 103 CALIF. L. REV. 841, 852 (2015).
17 See id. at 886.
18 See Gary M. Reisfield et al., Commentary, The Mirage of Impairing Drug
Concentration Thresholds: A Rationale for Zero Tolerance Per Se Driving under the
Influence of Drugs Laws, 36 J. ANALYTICAL TOXICOLOGY 353, 354 (2012).
19 Drug recognition experts are specialized officers who have been trained to
“detect[ ] and identify[ ] persons under the influence of drugs and in identifying” the
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THE SCIENCE OF DRUGGED DRIVING

A necessary prerequisite to any analysis of marijuana
DUI laws must focus on the scientific underpinnings of both DUI
jurisprudence and the chemistry behind marijuana and alcohol,
respectively. Any drug—including marijuana and alcohol—can
be potentially impairing if it affects a driver’s concentration,
awareness, judgment, or coordination.20 This part of the note will
thus concentrate its analysis on how impairment is measured
from a legal standpoint. The beginning of such an inquiry
largely centers on the chemistry of marijuana, examining its
significance in terms of policing and enforcing impaired-driving
laws in particular.21 The analysis then contrasts marijuana’s
impact on driver impairment to the effects felt by the alcoholimpaired driver.
A.

The DUI Alcohol Regime as a Backdrop for Marijuana
Law

In their effort to legalize recreational marijuana via
state and national legislation, lawmakers have often utilized
rhetoric and language that compares marijuana and alcohol for
political purposes.22 Even along the West Coast—where the
marijuana legalization movement first originated—users are
still aware of the stigma that is attached to marijuana use.23
type of drug that is the cause of an individual’s impairment. Drug Recognition Experts
(DRE), INT’L DRUG EVALUATION & CLASSIFICATION PROGRAM, http://www.decp.org/drugrecognition-experts-dre/what-they-do [https://perma.cc/59ZR-232S]. DREs are specially
trained to evaluate and analyze a person’s appearance, behavior, and vital signs in order
to make an informed decision regarding a person’s potential drug use. Id.
20 Importantly, driver impairment from marijuana, alcohol, or any other drug
should be assessed the same to the extent that it impacts one’s concentration,
coordination, or judgment while behind the wheel. See AAA FOUND. FOR TRAFFIC SAFETY:
IMPAIRED DRIVING, https://www.aaafoundation.org/impaired-driving [https://perma.
cc/2RE8-YUKX]. Obviously, deficiencies in these areas can be observed by police in
countless ways, such as: speed and braking problems, improper lane positions, swerving,
etc. See NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., DOT HS 808 677, THE VISUAL
DETECTION OF DWI MOTORISTS 4 (2010).
21 Driving impairment refers generally to the operating of a motor vehicle while
under the influence of an intoxicating substance, such as alcohol, marijuana, or other
drugs. See Impaired Driving, GOVERNORS HIGHWAY SAFETY ASS’N, http://ghsa.org/html/
issues/impaireddriving/index.html [https://perma.cc/6DHP-R7WF]. While all states have
laws regulating impaired driving, “[t]he alcohol-impaired driving laws are better
understood and easier to enforce than those for drug-impaired driving.” Id.
22 See, e.g., Matt Ferner, Two House Bills Would End Federal Prohibition of
Marijuana, HUFF. POST (Feb. 20, 2015), http://www.huffingtonpost.com/2015/02/20/
marijuana-legalization-congress_n_6722686.html [https://perma.cc/MBJ9-KGF4] (For
instance, Colorado legislators introduced the “Regulate Marijuana Like Alcohol Act.”).
23 Travis D. Satterlund et al., Stigma Among California’s Medical Marijuana
Patients, 47 J. PSYCHOACTIVE DRUGS 10, 14 (2015).
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While policymakers should be lauded for their attempt to
destigmatize marijuana use by comparing it to a more ubiquitous
drug like alcohol, these efforts ultimately misrepresent the
science, specifically as it relates to driving and impairment. While
ballot initiatives urging voters to “regulate and tax marijuana like
alcohol” have an obvious political appeal, they also have the
unfortunate effect of framing marijuana policy within the
confines of an alcohol policy regime.24 Unlike marijuana, the
impairing effects of alcohol on driving have been subject to
rigorous scientific study, testing, and analysis over the course of
several decades.25 Thus, lawmakers should be more than wary
of trying to fit marijuana DUI laws neatly into well-established
alcohol DUI policy regimes.
The extensive history of drunk driving in the United
States has been subject to significant scientific analysis and
research, which ultimately led to the establishment of a widely
regarded standard for impairment for intoxicated drivers.26 New
York criminalized the act of driving while intoxicated in 1910,
which case law further construed as the diminished “ability to
operate an automobile” while affected by alcohol.27 Given
alcohol’s distinctive water solubility, it can dissipate entirely
from the body via natural metabolism.28 Because of alcohol’s
metabolic characteristics, its concentration in bodily fluids at
any point is proportional to its absorption and elimination rates
from the body—rates that are similar (though not entirely
identical) among all people.29 Thus, as a result of alcohol’s
uniquely complete solubility in water, the concentration of
alcohol from one’s breath is relatively constant in relation to its
blood concentration ratio in arterial blood.30 This discovery
allowed scientists to conclude that BAC correlates positively,
and linearly, with the intensity of alcohol’s impairing “effect[s]
on the user’s central nervous system.”31 In 1931, scientist Dr.
Rolla Harger invented the “Drunk-O-Meter” to test users’

24 The Colorado ballot initiative legalizing the recreational use of marijuana for
adults was entitled “The Regulate Marijuana Like Alcohol Act.” See Ferner, supra note 22.
25 See, e.g., Roth, supra note 16, at 865.
26 See id. at 872–73.
27 Josephine Y. King & Mark Tipperman, The Offense of Driving While
Intoxicated: The Development of Statutory and Case Law in New York, 3 HOFSTRA L. REV.
541, 544–45 (1975) (providing background information on the rise of DUI laws).
28 Roth, supra note 16, at 852.
29 Id.
30 Id. (“In turn, one’s BAC is generally proportional, in a linear fashion, to the
intensity of the effect on the user’s central nervous system.”).
31 Id.
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breath for BAC32—the original predecessor to the common
breathalyzers used today.
In 1941, New York amended its DWI statute to permit
the admissibility of BAC test results in DWI cases.33 Similar to
the ways many states would grapple with early BAC-based
jurisprudence, New York developed an early statutory scheme
that relied heavily on BAC levels to adjudicate cases. Tests
resulting in a BAC of .05 or less provided prima facie evidence of
sobriety, while anything above .05 but below .15 was “relevant
evidence of intoxication,” and a BAC above .15 provided “prima
facie evidence of intoxication.”34 This statutory scheme, however,
ostensibly tolerated the impaired driver while criminalizing only
the intoxicated driver at the higher BAC threshold.
The post-War years led to a massive rise in DWI fatalities
as automobile culture accelerated through the 1950s and 1960s
leading to an eventual high of approximately 50,000 automobile
deaths each year.35 States responded accordingly as more
scientific research was able to correlate BAC levels with levels of
impairment and dangerousness, leading New York to establish a
.10 BAC as prima facie evidence of impairment under the state’s
new DWI law.36 Increasing scientific work, most notably by
famed New York bureaucrat and physician William Haddon
(who later became the first director of the National Highway
Traffic Safety Administration), started to focus on the relation of
BAC to dangerousness through crash-test studies.37 By the early
1970s, New York, along with almost every other state, had
established per se laws prohibiting driving with a .10 BAC or
above.38 The law and order era of the 1980s and 1990s saw the
rise in prominence of groups like Mothers Against Drunk
Driving (MADD), which were able to seize upon a changing
political landscape, as well as focusing events like the death of
Princess Diana, in pushing for an even lower .08 BAC per se
law.39 In 2000, President Bill Clinton started withholding
highway funding for states that did not meet the lower .08 BAC
per se standard.40 By 2004, every state and the District of
Columbia had established per se .08 BAC driving laws.41
32
33
34
35
36
37
38
39
40
41

See id. at 853.
King & Tipperman, supra note 27, at 546.
Id. at 546–47.
Roth, supra note 16, at 863.
King & Tipperman, supra note 27, at 563.
Roth, supra note 16, at 864–65, 867.
King & Tipperman, supra note 27, at 578–79.
Roth, supra note 16, at 872–73.
Id.
Id.
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The Impact of Marijuana on Driving Impairment

Marijuana’s unique chemical properties—particularly
the way its various compounds interact within the human
body—make it markedly different from other potentially
intoxicating substances, especially with regard to how it is
measured and its impact on driving ability. The main psychoactive
component in marijuana is delta-9-tetrahydrocannabinol (THC),
the compound that causes the impairment most associated with
marijuana use.42 Importantly, it is THC that gives marijuana so
many of its unique properties as a drug; specifically, the mere
presence of THC in the body can provide little information as to
when the drug was used, how much was used, and its current
impairing effect on the user.43 Unlike alcohol, which is
eliminated from the body quickly and in a steady, linear
fashion, THC is much more fat-soluble and thus concentrates
largely within the fatty adipose tissue of the human body.44 As
a result of the highly fat-soluble nature of THC, its functional
impairing effects may maximize up to an hour after
inhalation,45 while blood levels of THC spike within minutes of
inhalation, before quickly decreasing in concentration.46
Consequently, while blood concentrations of THC will spike
quickly after usage, the effects of THC can lag for some time.
Ultimately, this is one of the main reasons why scientists have
struggled to correlate blood levels of THC with actual impairment,
particularly when compared to the ease of doing so with alcohol.47
Perhaps the most inimitable and problematic
characteristic of THC is that its impairing effects are highly
variable among individuals depending on numerous additional
factors, particularly the chronicity of use.48 Studies have found
42 See Franjo Grotenhermen et al., Developing Limits for Driving Under
Cannabis, 102 ADDICTION 1910, 1911 (2007).
43 See id.
44 R. Andrew Sewell et al., The Effect of Cannabis Compared with Alcohol on
Driving, 18 AM. J. ON ADDICTIONS 185, 188 (2009).
45 Inhalation remains the most common method of using marijuana. How
Marijuana Is Consumed, DRUG POLICY ALL., http://www.drugpolicy.org/facts/drug-facts/
marijuana/how-marijuana-consumed [https://perma.cc/85MT-GQQB]. For the sake of this
note, assume that “marijuana use” or “usage” refers to the inhalation of marijuana smoke
unless otherwise stated. Other methods of marijuana ingestion exist (such as inhaling
vaporized THC or consuming edible foods containing THC) and are becoming increasingly
prevalent. See Leafly Chart of the Month: What’s the Most Popular Form of Cannabis in
Your State, LEAFLY, https://www.leafly.com/news/industry/leafly-chart-of-the-month-whatsthe-most-popular-form-of-cannabis/ [https://perma.cc/R6Q5-6JLX].
46 Sewell et al., supra note 44, at 188.
47 Id.
48 Mark J. Neavyn et al., Medical Marijuana and Driving: A Review, J. MED.
TOXICOLOGY 269, 271 (2014).
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high concentrations of THC in the blood of chronic marijuana
users many days after last usage, when the impairing effects
have long worn off.49 The fat-soluble nature of THC enables it to
be stored in human fat tissue for a variable period of time while
gradually being released back into the bloodstream anywhere
from a day for an occasional user, to several weeks for a chronic
user.50 Consequently, the occasional smoker who inhales from a
marijuana cigarette may test negative for THC in blood samples
a few days later (or less), while a chronic user who abstains for
several weeks may still test positive for THC.51 It is precisely
here where the science behind marijuana complicates the law
with regards to testing for DUIs.
1. Idiosyncrasies of Blood and Urine Testing
Once THC is circulating in the bloodstream, it begins to
break down into its ultimate inactive metabolite form, 11-nor-9carboxy-THC (Carboxy-THC), which is “the most ubiquitous THC
metabolite found in urine” samples.52 Carboxy-THC can stay
present in the bloodstream for months depending upon the
frequency of marijuana use.53 However, “the qualitative
measurement of [Carboxy-THC] metabolite in urine does not
correlate with either time of ingestion or active intoxication. This
dilemma has led investigators to pursue alternative testing to
determine marijuana intoxication and predict time of
ingestion.”54 From a legal standpoint, this makes testing for the
presence of THC difficult for law enforcement conducting routine
traffic stops. Unable to utilize roadside urine testing—because
such tests cannot reliably determine impairment levels for
marijuana (beyond the fact that such tests are not practical)—
law enforcement has increasingly come to rely on whole blood or
blood serum samples in order to more accurately test for THC.55
Unfortunately, even such whole blood and blood serum
samples have proven to be unreliable for determining THC

49 Erin L. Karschner et al., Do Δ9-Tetrahydrocannabinol Concentrations
Indicate Recent Use in Chronic Cannabis Users?, 104 ADDICTION 2041, 2046 (2009).
50 See How Long Does Cannabis Stay in the Body After Smoking?, NHS
CHOICES, http://www.nhs.uk/chq/Pages/2287.aspx?CategoryID=53 [https://perma.cc/8H
83-8J7R] (last updated July 1, 2016).
51 See id.
52 Neavyn et al., supra note 48, at 271.
53 Id.
54 Id. at 273.
55 Id.; see, e.g., MONT. CODE ANN. § 61-8-411 (2015) (Montana DUI statute
focusing on blood samples to test for THC).
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levels, let alone impairment.56 Since marijuana has a half-life57 of
over two months, “[i]n chronic cannabis users[ ] it is particularly
difficult to determine whether a positive result for cannabis
[from a blood test] represents a new episode of drug use or
continued excretion of residual drug.”58 Not only are blood
samples therefore subject to a vast amount of variability
depending on the individual’s chronicity of marijuana use, but
blood samples are practically difficult to obtain and lack accuracy
in other ways. Crucially, “[i]t is more difficult to persuade
randomly stopped drivers to submit to a blood test for THC than
to a breath test for BAC, and other tests for THC—such as saliva
and urine—are currently less accurate than blood and may
underestimate THC blood level.”59 Additionally, in cases involving
car accidents in which samples may not be collected for hours
after the incident, urine samples are likely to be overinclusive—
since THC is slowly released from fat cells into urine even weeks
after use—while blood samples can possibly be underinclusive for
THC60—since the blood sample itself continuously metabolizes
THC to its inactive metabolite, Carboxy-THC.61
While marijuana use presents new issues with regard to
a proper testing methodology for THC, it also presents issues
with regard to whether THC metabolites should also be tested
for, and, if so, how such tests might factor into the equation for
determining legal levels of marijuana impairment. Many state
DUI statutes include a prohibition on marijuana metabolites,
including the inactive Carboxy-THC.62 Although there may
56 See Mateus M. Bergamaschi et al., Impact of Prolonged Cannabinoid
Excretion in Chronic Daily Cannabis Smokers’ Blood on Per Se Drugged Driving Laws,
59 CLINICAL CHEMISTRY 519, 525 (2013).
57 “Half-life” is defined as “the time required for half the amount of a substance
(as a drug, radioactive tracer, or pesticide) in or introduced into a living system or
ecosystem to be eliminated or disintegrated by natural processes.” Half-life, MERRIAMWEBSTER.COM, http://www.merriam-webster.com/dictionary/half–life [https://perma.cc/
5S93-U6PN].
58 Priyamvada Sharma et al., Chemistry, Metabolism, and Toxicology of
Cannabis: Clinical Implications, 7 IRANIAN J. PSYCHIATRY 149, 152 (2012).
59 Roth, supra note 16, at 901–02.
60 See Jared D. Adams, New Issues in Driving Under the Influence of Cannabis
Cases, in UTILIZING FORENSIC SCIENCE IN CRIMINAL CASES 59 (2013) (“[I]n cases involving a
serious accident where the blood sample is not collected until several hours after driving, it
is possible that the result could come back negative for [THC], but positive for carboxy-THC.
In this scenario, it is conceivable that the prosecution could argue that the driver was under
the influence. However, an occasional user can test positive for some level of [Carboxy-THC]
up to seven days after consumption. Thus, the results of this test do not conclusively
determine whether a driver was or was not under the influence.”).
61 See id. at 58–59.
62 See, e.g., UTAH CODE ANN. § 41-6a-517(2) (West 2016). But cf., OHIO REV.
CODE ANN. § 4511.19(A)(1)(j)(vii)–(viii)(I) (West 2016) (Some states, such as Ohio, have
established numbered per se laws for a specified concentration of marijuana metabolites
allowed in a driver’s blood.).
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remain some moral justification for prohibiting or limiting the
concentration of marijuana metabolites in the blood of drivers—at
least in states with blanket marijuana prohibitions—such policies
are simply unsupported by the scientific literature and are often
based on political expediency and moral disapproval of the drug.63
This legal battle is currently playing out in a medical
marijuana state, Arizona, where the state court of appeals
recently held that any amount of THC or “impairing metabolite”
could uphold a DUI conviction, regardless of actual driver
impairment or status as a medical marijuana patient.64
Accordingly, a legal medical marijuana patient in Arizona would
likely always be driving with at least some level of THC
metabolites in his or her blood system even during a prolonged
period of abstinence.65 The prohibition of metabolites persists in
Arizona despite conclusive research detailing the nonpsychoactive features of the main THC metabolite, CarboxyTHC.66 Thus, the presence of Carboxy-THC in the blood of a
driver serves no scientific purpose with regards to measuring
impairment levels. In states with a blanket prohibition on
marijuana, such a proscription can, at the very least, be
supported by general moral disapproval of a drug that is
statutorily illegal to possess or consume. Hence, per se laws
prohibiting even non-psychoactive marijuana metabolites in
drivers could be justified under a jurisprudence of prohibition
while being logically connected to a legitimate penal goal.67 Once
a state has legalized medicinal or recreational use of the drug,
however, per se prohibitions on the non-psychoactive metabolite
of THC—and perhaps THC itself—can no longer be justified
under a jurisprudence of prohibition and moral condemnation.
When marijuana is legalized in some form, “a
prohibitionist approach is an awkward fit if the justification for
the law is the dangerousness of the drug’s impairing effects,
rather than simply the immorality of using the drug.”68 Marijuana
63 See Mark Hansen, Drugged State: Ohio Pushes for Tough Laws for Drivers,
Critics Question Impairment Issue, 91 ABA J. 12, 14 (2005).
64 Dobson v. McClennen, 337 P.3d 568, 574 (Ariz. Ct. App. 2014) (citing State ex
rel. Montgomery v. Harris, 322 P.3d 160, 164 (Ariz. 2014)), vacated, 361 P.3d 374 (2015).
This legal battle is still ongoing and was recently vacated by the Arizona Supreme Court.
Dobson v. McClennen, 361 P.3d 374, 375 (Ariz. 2015). This litigation will be discussed in
further detail later in this note. See infra Part II.A.
65 See Bergamaschi et al., supra note 56, at 519 (“Cannabinoids can be detected
in blood of chronic daily cannabis smokers during a month of sustained abstinence.”).
66 István
Ujváry
&
Franjo
Grotenhermen,
11-Nor-9-Carboxy-∆9Tetrahydrocannabinol—A Ubiquitous Yet Underresearched Cannabinoid: A Review of
the Literature, 9 CANNABINOIDS 1, 5 (2014).
67 Roth, supra note 16, at 889.
68 Id. at 890.
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DUI laws should be based upon actual driver impairment and not
merely the presence of particular chemical compounds that
provide little justification in hard science to indicate impairment.
2. Unique Impairing Effects of THC
It is not just the non-psychoactive metabolites of THC
that have made DUI marijuana laws so problematic, but also
the inherently unique impairing effects of the psychoactive
THC itself. It is widely accepted that there is at least “a
general correlation between blood THC levels and driving
impairment.”69 The research also shows, however, that frequent
marijuana users develop a tolerance that minimizes impairment
at a given THC dosage, as compared to infrequent users given
the same THC dosage.70 Similar studies have also failed to find a
relationship between impairment and blood concentrations,
since “peak impairment often does not correlate with peak blood
drug concentration.”71 Furthermore, blood concentrations of THC
decline rapidly in the human body, so concentrations may be
much lower when the sample is collected than when any
incident, or alleged impairment, actually occurred.72
What is perhaps even more confounding for any sciencebased approach to DUI standards is that marijuana impairment
is often mitigated by drivers’ self-awareness and overestimation
of their own level of impairment.73 Cannabis users tend not only
to overestimate the level of their impairment—particularly
when compared to alcohol users—but consciously try to mitigate
such impairment by taking actions like driving slower and
increasing their attention to the road.74 “[D]rivers under the
influence of cannabis may compensate consciously for some of
the impairment of their automatic performance, for example by
reducing speed or keeping more distance.”75 The use of
impairment-mitigation tactics, as described, provide further
evidence that increased levels of THC do not necessarily correlate
Reisfield et al., supra note 18, at 354.
Id. This type of tolerance differs in significant ways from alcohol tolerance
which will be discussed later in this note. See infra Part I.C.
71 Reisfield et al., supra 18, at 354.
72 Id.
73 Eduardo Romano et al., Drugs and Alcohol: Their Relative Crash Risk, J. STUD.
ON ALCOHOL & DRUGS 56, 62 (2014); see Grotenhermen et al., supra note 42, at 1913.
74 Grotenhermen et al., supra note 42, at 1913; Romano et al., supra note 73,
at 62. In on-road studies “[t]he impairment caused by cannabis appeared to be partially
mitigated because subjects were aware of their impairment and, where possible, tended
to compensate by not overtaking, by slowing down and by focusing attention in
anticipation of a required response.” Grotenhermen et al., supra note 42, at 1913.
75 Grotenhermen et al., supra note 42, at 1915.
69
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positively with actual driver impairment—particularly when
compared to alcohol users who tend to underestimate their level of
impairment.76 Such evidence lends even more credence to a
marijuana DUI regime based upon actual driving impairment,
rather than one based upon blood levels of THC or its metabolites.
Perhaps the most interesting finding has been the direct
positive link between legalized marijuana and decreased traffic
fatalities—particularly traffic fatalities involving alcohol.
Researchers have found that states with medical marijuana
laws have seen on average an 8-11% drop in total traffic fatalities
and a 13.2% decrease in all alcohol-related traffic fatalities in the
first year of the laws’ implementation.77 One hypothesis for this
decrease is that in states that have legalized marijuana, it is
increasingly used as a substitute for alcohol.78 This is one
theory why Colorado traffic fatalities hit historic lows in each
subsequent year since the state legalized marijuana in 2012.79
It has also been theorized that since most marijuana use takes
place at home—as opposed to the bars and restaurants alcohol
drinkers congregate in—marijuana users are simply less likely
to be in a situation where they may drive while impaired.80
Even if some societal factors are the reason why marijuana use
has led to decreased traffic fatalities, this at least bodes well
from a harm reduction standpoint.
C.

A Comparison of Drunk Driving and Drugged Driving

All of the chemical properties that created the sciencebased jurisprudence of a BAC-based DUI law for alcohol are
nonexistent in marijuana. One major reason it is so difficult to
measure marijuana impairment compared with alcohol
impairment is that marijuana contains 421 chemicals, 61 of
76 “Researchers also concluded Cannabis-influenced drivers ‘may attempt to
drive more cautiously to compensate for impairing effects, whereas alcohol-influenced
drivers often underestimate their impairment and take more risk.’” René Marsh, Fed
Study: Booze Impact Greater than Pot on Driving, CNN (June 25, 2015), http://www.
cnn.com/2015/06/24/politics/marijuana-study-drivers-impact/ [https://perma.cc/X94U-FJUL];
see Romano et al., supra note 73, at 62.
77 D. Mark Anderson et al., Medical Marijuana Laws, Traffic Fatalities, and
Alcohol Consumption, 56 J.L. & ECON. 333, 347–49 (2013).
78 Id. at 359.
79 See Radley Balko, Since Marijuana Legalization, Highway Fatalities in
Colorado Are at Near-Historic Lows, WASH. POST (Aug. 5, 2014), https://www.washington
post.com/news/the-watch/wp/2014/08/05/since-marijuana-legalization-highway-fatalities-i
n-colorado-are-at-near-historic-lows [https://perma.cc/65AN-2JYK]; see also Jacob Sullum,
More Pot, Safer Roads: Marijuana Legalization Could Bring Unexpected Benefits, FORBES
(Apr. 3, 2014), http://www.forbes.com/sites/jacobsullum/2014/04/03/more-pot-safer-roadsmarijuana-legalization-could-bring-unexpected-benefits/#10f82e663781.
80 Anderson et al., supra note 77, at 335.
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which are cannabinoids,81 while alcoholic beverages only have
one psychoactive chemical—ethyl alcohol (also referred to as
ethanol or simply alcohol). As discussed above, alcohol follows a
linear metabolic route with little individual variability, allowing
it to be detected with high precision—unlike marijuana.82 The
highly variable nature of marijuana makes it difficult to test
when a person last used marijuana and the degree to which that
person may or may not be currently impaired. Put simply, the
fact that marijuana stays in the human body for days after
usage, and that dosages of THC create relatively variable levels
of impairment depending on individual tolerance, make it nearly
impossible to accurately determine if someone is impaired by
marijuana at a given time via blood testing.83
Despite certain scientific advancements in cannabis
detection, the underlying issue of impairment still remains a
variable factor. In April 2015, two University of Akron graduate
students developed a device that measures THC levels via a
noninvasive, roadside saliva test.84 The aptly dubbed
“Cannibuster,” along with other similar devices, are admirable
efforts in improving THC testing at the precise time of any
alleged impairment or incident.85 State legislatures should be
wary, however, of quickly adopting such devices to enforce
marijuana DUI laws considering that THC levels still do not
correlate directly with impairment at equal levels among all
individuals. Therefore, these devices still do not provide an
accurate measure of driver impairment and should not be relied
upon as evidence.86 Since even small dosages of THC can easily
stay present in the body with no impairing effects for over a
month,87 devices like the “Cannibuster” will do little to tell us
about actual driver impairment. Such tests could potentially be
underinclusive as well by providing a negative or low-test
result for THC in the blood when brain concentrations of the
chemical are still sufficient to cause impairment.88 Strict reliance

Sharma et al., supra note 58, at 149.
Sewell, supra note 44, at 188.
83 See id.
84 See Molly Brown, Meet the Cannibuster, the Latest Breathalyzer for Marijuana,
GEEKWIRE (Apr. 30, 2015), http://www.geekwire.com/2015/meet-the-cannibuster-the-latestbreathalyzer-for-marijuana [https://perma.cc/F97F-7ZYJ].
85 See id.
86 See Bergamaschi et al., supra note 56, at 524–25 (Since more habitual
users can test positive for THC “days to weeks after initiation of abstinence,” such
devices are not particularly probative of impairment.).
87 See id. at 519.
88 See id. at 520–21 (“Thus, blood concentrations may be low or not detected while
brain concentrations might be sufficient to cause impairment. These pharmacokinetic
81
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on such technology would inevitably enable some drivers to skirt
marijuana DUI laws despite their actual impairment.
Ultimately, machines such as the “Cannibuster” may provide
law enforcement with data regarding previous marijuana use,
but still fail to accurately gauge actual driver impairment in the
same way that a breathalyzer measures alcohol impairment.
While the focus for decades within alcohol DWI law has
been on the strong correlation between BAC and relative crash
risk,89 such a simple correlation does not exist for marijuana. It
is not merely scientists who realize that alcohol acts, and can be
tested, in a way that is unlike most other drugs. A 1985 report
on drugged driving by the New York State legislature illustrates
policymakers’ awareness of the issue:
The ability to define drug impairment is constrained primarily by
the pharmacokinetics of drugs. Unlike alcohol, a single substance
with a simple chemical structure, other drugs contain numerous
substances and are often chemically complex.
. . . These drugs may remain in the body for long periods of time . . . .
In other cases, drug presence may be detected after the drug’s
impairment action effectively has ceased. In addition, individuals
respond differently to the same dose or the same drug concentration
and chronic users can tolerate higher doses than individuals
receiving an initial single dose of the drug. Unlike alcohol, . . . drugs
are metabolized much more quickly and a higher level of a drug does
not always correlate positively with a higher degree of impairment.90

Since the report was published in 1985, few things regarding the
science behind marijuana impairment testing have changed.
Indeed, as previously detailed, a policy regime that is
accustomed to relying on BAC for DWI convictions is poorly
equipped to handle incidents of marijuana impairment.
What has changed, though, is the rapid transformation of
the state laws governing the use of marijuana—from a law and
order era of prohibition, to an era of increasingly progressive
acceptance of marijuana for both medical and recreational
purposes. Marijuana’s presently unique status as a drug on the
verge of being accepted as having both sanctioned medicinal and
recreational purposes puts lawmakers on the frontier of a new
legal landscape. If the drug is accepted for either medical or
characteristics make it difficult to identify a minimum blood THC concentration consistently
associated with impairment.”).
89 See H. LAURENCE ROSS, CONFRONTING DRUNK DRIVING 20–21 (1992).
90 N.Y. STATE LEGISLATURE, COMM’N ON CRITICAL TRANSP. CHOICES, THE DRUG
IMPAIRED DRIVER: HOW MUCH TOUGHER SHOULD NEW YORK STATE’S ANTI-DRUNK
DRIVING LAWS BE? 13–14 (1985) (footnotes omitted) [hereinafter INTERIM REPORT: THE
DRUG IMPAIRED DRIVER].
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recreational purposes, or both, lawmakers must create DUI laws
that allow for its realistic use and consumption, since moral
condemnation can no longer be used as a penal justification for
marijuana DUI laws. These potential developments lead to the
inevitable question of whether medical marijuana users should
be subject to the same DUI laws as recreational users.
Additionally, what types of protections should medical and
recreational marijuana users be afforded, if any, so that
marijuana DUI laws do not convict innocent people but can still
convict those guilty of actual driving impairment?
These questions may be answered by exploring three
states with different levels of marijuana legalization and
different statutory regimes for marijuana DUI laws. Arizona
legalized the medicinal use of marijuana in 2010.91 Since
passage of the legislation, the marijuana DUI laws have been
hotly contested in courts as prosecutors were able to convict
medical marijuana users for DUIs via a per se prohibition on
THC and its metabolites.92 Colorado passed medical and
recreational marijuana laws in 1998 and 2012, respectively,93
while creating a “permissible inference” marijuana DUI standard
based upon THC blood levels.94 New York recently implemented
its 2014 bill aiming to legalize medical marijuana,95 yet kept its
“ability impaired” standard without revision, despite
marijuana’s changing legality.96 These states can provide an
overview of various marijuana DUI regimes, the benefits of such
laws, and the various pitfalls and problem areas associated with
such murky legal territory.

91 Arizona Voters Approve Medical Marijuana Measure, CNN (Nov. 14, 2010),
http://www.cnn.com/2010/POLITICS/11/14/arizona.medical.marijuana [https://perma.c
c/K4WH-NX9K].
92 See Paul Davenport, Court: No Medical Marijuana Immunity Under
Arizona DUI Law, THE CANNABIST (Nov. 20, 2015), http://www.thecannabist.co/2015/11/
20/court-no-medical-marijuana-immunity-under-arizona-dui-law/44206/.
93 Tiftickjian, History of Marijuana Legislation in Colorado, supra note
10, at 1, 2–3.
94 Jay M. Tiftickjian, Driving Under the Influence of Drugs: An Overview of
Colorado’s Alcohol and Drug-Related Driving Offenses, in MEDICOLEGAL ASPECTS OF
MARIJUANA: COLORADO EDITION, supra note 10, at 85, 89 [hereinafter Tiftickjian,
Colorado’s Alcohol & Drug-Related Driving Offenses].
95 See Danny Spewak, State Takes Another Step Toward Medical Marijuana
Access, WGRZ.COM (Oct. 21, 2015), http://www.wgrz.com/story/news/2015/10/21/anotherstep-toward-medical-marijuana/74365878 [https://perma.cc/3GH6-VERG].
96 N.Y. VEH. & TRAF. LAW § 1192(4) (Mckinney 2016).
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II.

STATE MARIJUANA DUI LAWS: ARIZONA, COLORADO, AND
NEW YORK

A.

Arizona

Since its 2010 legalization of medical marijuana, Arizona’s
per se marijuana DUI laws have been subjected to intense
scrutiny in the courts as medical marijuana patients have
become increasingly frustrated with the vague language of the
pertinent statutes.97 The problem in Arizona stems from the
ambiguous and superficially contradictory nature of its statutes
concerning medical marijuana and drug DUIs. The Arizona
Medical Marijuana Act (AMMA) specifically prohibits the
[o]perating, navigating or being in actual physical control of any
motor vehicle, aircraft or motorboat while under the influence of
marijuana, except that a registered qualifying patient shall not be
considered to be under the influence of marijuana solely because of
the presence of metabolites or components of marijuana that appear
in insufficient concentration to cause impairment.98

The AMMA seemingly provides fundamental protections for
medical marijuana patients against DUI prosecutions
stemming from the mere presence of marijuana metabolites in
the body. The AMMA even goes as far as to apparently protect
against prosecutions based on the presence of “components of
marijuana”—presumably such as THC—that fail to appear in
sufficient concentrations to cause impairment.99
Arizona’s statutory scheme, according to the AMMA,
facially appears to provide important protections to legal
medical marijuana patients. Under the AMMA, medical
marijuana patients would presumably not have to worry about
marijuana DUI convictions based upon non-active metabolites
found days or weeks after last usage. Patients would also,
theoretically, not have to worry about their THC concentrations
as long as they are not actually impaired. Accordingly, the
AMMA seems to emphasize a marijuana DUI theory based
upon impairment, as opposed to one based upon scientifically
ambiguous test results of marijuana metabolites or THC. The
statutory guidelines for a DUI, however, directly contradict the

97 See Brian Skoloff, Ariz. Court: Pot Metabolite Test Not Enough for DUI
Conviction, THE CANNABIST (Apr. 22, 2014), http://www.thecannabist.co/2014/04/22/
arizona-court-rules-dui-law-impairment-marijuana-users/10209/ [https://perma.cc/29W
8-XSXE].
98 ARIZ. REV. STAT. § 36-2802(D) (West 2016) (emphasis added).
99 Id.
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spirit and purpose100 of the AMMA by prohibiting driving
“[w]hile there is any drug defined in section 13-3401 or its
metabolite in the person’s body.”101 The conflicting nature of the
two laws is apparent when one realizes that both “cannabis”
and “marijuana” are explicitly listed as prohibited substances
in Section 13-3401.102 Hence, the AMMA and Arizona’s current
DUI statute directly contradict each other with regard to their
treatment of marijuana and its metabolites. This tension has
slowly started to play itself out in the Arizona courts where it
remains a litigated issue today.
The incongruous nature of Arizona’s medical marijuana
and drug DUI laws has been center-stage in the case of Dobson
v. McClennen.103 Krishna Dobson and Marvelle Anderson were
convicted in Arizona for driving with marijuana metabolites
present in the body pursuant to § 28-1381(A)(3) (the DUI
statute) despite having valid medical marijuana cards at the
time that were excluded from evidence and became the main
issue on appeal.104 Dobson and Anderson asserted that they had
the right to submit into evidence their medical marijuana
registration identification cards because the AMMA provides
an affirmative defense to a DUI charge under the DUI statute.
The Arizona Court of Appeals, however, utilizing a strict
textualist approach to the law, argued that it “must assign to
each word its ‘usual and commonly understood meaning’ unless
the Legislature ‘clearly intended’ otherwise.”105 The court
reasoned that, in order to invoke the affirmative defense provided
by the AMMA, the defendants must show that they “took a
‘prescription drug[ ] as prescribed’ by a specified medical
practitioner,” and that Dobson and Anderson “cite no authority
suggesting that ‘as prescribed’ is intended to include a ‘written
certification’ as used in the AMMA.”106 The state court of
appeals thus rendered the protective nature of the AMMA for
drivers virtually obsolete. By excluding the medical marijuana
certificate given by a doctor from the definition of “as prescribed,”
as provided by the prescription drug exception in the DUI
100 See Daniel G. Orenstein, Voter Madness? Voter Intent and the Arizona
Medical Marijuana Act, 47 ARIZ. L.J. 391, 410–11 (2015) (discussing the spirit and
purpose of the AMMA in the context of impaired driving laws).
101 ARIZ. REV. STAT. § 28-1381(A)(3) (West 2016).
102 See id. § 13-3401(4), (19).
103 See generally Dobson v. McClennen, 337 P.3d 568, 570–71 (Ariz. Ct. App.
2014) (“Petitioners’ arguments implicate provisions of the Arizona Medical Marijuana
Act (AMMA), passed by Arizona voters in November 2010 . . . .”).
104 Id. Only one of the petitioners had an Arizona medical marijuana card. Id.
at 571. The other petitioner’s medical marijuana card was from Oregon. Id.
105 Id. at 572.
106 Id. at 572–73 (alteration in original).
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statute,107 the court concluded that the AMMA merely sanctions a
“written certification” for marijuana, but not a “prescription” for
marijuana.108 By differentiating between a “written certification”
and a “prescription,” the court held that such medical marijuana
certifications fall outside the parameters of the DUI statute’s
exception for prescription drugs.109
The court continued its argument by noting that
marijuana is a Schedule I controlled substance (despite passage
of the AMMA), and thus, no physician may prescribe it since
Schedule I drugs by definition lack any acceptable medical
use.110 The court’s holding left authorized medical marijuana
patients in Arizona without any protection from the state’s
strict per se DUI drug laws. The holding went against the intent
and spirit of the AMMA by preventing authorized medical
marijuana patients from presenting evidence of their marijuana
certifications as an affirmative defense against the state’s DUI
drug laws.
The Arizona Court of Appeals did not stop by simply
construing the prescription drug exception narrowly, but
continued by explicitly gutting the AMMA of its marijuana DUI
protections. The court concluded its argument by asserting that
“[p]etitioners were not prosecuted or penalized for using or
possessing marijuana; they were prosecuted and penalized for
driving after having used marijuana. Petitioners’ use of
marijuana while having valid registry identification cards did
not mean they could then drive or control a vehicle without
violating (A)(3).”111 In essence, the court asserted that the DUI
statute criminalizing the presence of marijuana metabolites in
drivers takes precedence over the AMMA’s explicit prohibition
on the prosecution of certified medical marijuana patients for
the presence of marijuana metabolites while driving. This is an
assault on the intent and spirit of the AMMA voter initiative to
protect medical marijuana users just like Dobson.112
While petitioners’ argument that the AMMA provides
blanket immunity for medical marijuana patients from
marijuana DUI prosecutions is incongruent with the prescription
drug exception—and purely illogical in light of basic safety
precautions—the AMMA does explicitly provide an affirmative
defense for certified marijuana patients from prosecution under
107
108
109
110
111
112

See ARIZ. REV. STAT. § 28-1381(D) (West 2016).
Dobson, 337 P.3d at 573.
See Orenstein, supra note 100, at 401–02 (analyzing the Dobson decision).
See Dobson, 337 P.3d at 573.
Id. at 574.
See Orenstein, supra note 100, at 418.
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the DUI statute. The affirmative defense provided by the AMMA
is the type of basic protection medical marijuana patients
should have from DUI prosecutions and is consistent with the
prescription drug exception already on the books in Arizona.113
Eventually, the Arizona courts would move in favor of this type
of affirmative defense as a logical solution.114
Despite Arizona’s hazy marijuana DUI laws, it appeared
for a time that the state courts would provide some clarity to
the issue when a state court of appeals case essentially
overturned the prohibition on marijuana metabolites in drivers
that had been established by Dobson.115 In Montgomery v. Harris,
defendant Hrach Shilgevorkyan was pulled over by police for
speeding and making unsafe lane changes, and was arrested
for a DUI when blood samples—obtained after he told police he
had smoked marijuana the previous night—revealed the presence
of Carboxy-THC.116 The court asserted that:
The State’s interpretation that “its metabolite” includes any byproduct of a
drug listed in § 13-3401 found in a driver’s system leads to absurd
results . . . .
Most notably, this interpretation would create criminal liability
regardless of how long the metabolite remains in the driver’s system or
whether it has any impairing effect.117

The court correctly noted that Carboxy-THC can stay in a
person’s body for up to thirty days after ingestion, and therefore
prosecuting a driver for having an inactive metabolite could lead
to criminalizing otherwise legal conduct under the AMMA.118
Despite the court’s best efforts to provide a science-based
approach to the metabolite law, the Arizona Court of Appeals
failed to extend the central holding, instead asserting that
“Harris is not a significant change in the law—it is merely the
first case to address the ambiguity of the phrase ‘its
metabolite.’”119 It seemed the case law regarding even the
presence of mere inactive metabolites remained obscure, let alone
See ARIZ. REV. STAT. § 28-1381(D) (West 2016).
The Supreme Court of Arizona eventually granted certiorari in Dobson—as
discussed in detail later, see infra pp. 20–21, and held that “the AMMA does not immunize a
medical marijuana cardholder from prosecution under § 28–1381(A)(3), but instead affords
an affirmative defense if the cardholder shows that the marijuana or its metabolite was in a
concentration insufficient to cause impairment.” Dobson v. McClennen, 361 P.3d 374, 375
(Ariz. 2015).
115 See Skoloff, supra note 97.
116 State ex rel. Montgomery v. Harris, 322 P.3d 160, 160 (Ariz. 2014).
117 Id. at 162 (citation omitted).
118 Id. at 162–63. As the court describes, this would lead to the bizarre result
whereby medical marijuana patients would effectively be prohibited from driving since
they could have Carboxy-THC in their system for weeks after abstinence. See id.
119 State v. Werderman, 350 P.3d 846, 848 (Ariz. Ct. App. 2015) (footnote omitted).
113
114
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the law regarding the presence of actual THC, which can also
remain in the body for long periods of time without impairing
effects. Even in the aftermath of Harris, conservative lawmakers
pushed back against the court’s central holding by attempting to
enact legislation that would explicitly prohibit the presence of
active or inactive marijuana metabolites in drivers.120 Fortunately
for medical marijuana patients, the Arizona Supreme Court
stepped in and granted certiorari in the Dobson case to clear the
conflicting nature of the AMMA and marijuana DUI laws.
The Arizona Supreme Court, finding Dobson’s argument
that the AMMA gives absolute immunity from the DUI statute
unpersuasive, held that the AMMA provides a limited
affirmative defense to a DUI charge.121 The court in dicta
criticized the DUI statute for “cast[ing] a net that embraces
drivers who have proscribed drugs or their impairing metabolites
in their bodies but who may or may not be impaired.”122 Despite
such language, the court was still unwilling to go so far as to
provide the type of affirmative defense available to prescription
drug users under the DUI statute’s prescription drug
exception—asserting instead that there remains a significant
enough difference between the “written certification” that medical
marijuana patients receive and the “prescription” typically given
by doctors.123 Instead of allowing medical marijuana
“certifications” to be considered equal to regular “prescriptions,”
which would allow marijuana patients access to the already wellestablished affirmative defense available for patients with
“prescriptions” under section 28–1381(D), the court consigned
marijuana patients to reliance on the AMMA for protection.124
This reasoning is both practical and prudent in light of the way
in which medical marijuana is currently used by patients.
Marijuana dosing—unlike dosing for drugs covered by the DUI
statute’s prescription drug exception—is an inexact science and
varies considerably between individuals.125 Given the lack of
research and the immense degree of individual variability in
marijuana’s impairing effects, it is logical to conclude that a
patient, and not a physician, will have a better sense of their

120 See Ray Stern, Sonny Borrelli’s DUI Bill Targets Medical-Cannabis Users With
“Inactive” Metabolites, PHX. NEW TIMES (Jan. 28, 2015), http://www.phoenixnewtimes.com/
news/sonny-borrellis-dui-bill-targets-medical-cannabis-users-with-inactive-metabolites-6644
340 [https://perma.cc/YC5B-AVZD].
121 Dobson v. McClennen, 361 P.3d 374, 377 (Ariz. 2015).
122 Id.
123 Id. at 377–78.
124 Id.
125 See supra Part I (detailing the science of marijuana at length).
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own tolerance to marijuana, as well as the amount of marijuana
necessary to achieve the desired medicinal effect.126
Arizona provides the interesting case of a state attempting
to enforce per se DUI laws on marijuana, and its metabolites,
while attempting to accommodate a coexisting medical marijuana
regime. While the current state of Arizona’s marijuana DUI law
remains messy, and can lead to “absurd” results, there are certain
aspects of the AMMA that—with the added safeguards of the
affirmative defense as announced by the most recent Dobson
decision127—could provide at least a basis for a more rational,
science-based approach to marijuana DUI laws. As of now,
Arizona proscribes the presence of any amount of THC or its
metabolites in the body of a driver, but at least provides an
affirmative defense for certified patients to prove such quantities
were insufficient to create impairment.128 The availability of
expert witnesses to testify as to a specific individual’s impairment
level and tolerance will likely be crucial in asserting an
affirmative defense under the AMMA. The Arizona state courts
would be wise to allow the liberal use of such expert testimony
and scientific research at DUI trials until research advances
within the field.129
See Dobson, 361 P.3d at 378.
The affirmative defense provided by the AMMA, and discussed in Dobson,
was recently put into issue in Arizona v. Robbins. Arizona v. Robbins, No. 1 CA-CR 150584, 2016 WL 4894863 (Ariz. Ct. App. Sept. 15, 2016). Raymond Robbins, a medical
marijuana patient from Arizona, was stopped by police after exhibiting erratic driving
behavior. Id. at *1. When officers asked Robbins for his identification, he instead
presented his AMMA card since he was unable to locate his driver’s license. Id. Robbins
also told police he had smoked marijuana approximately two hours before being stopped.
Id. An officer trained in DUI detection arrived shortly after the stop to administer a field
sobriety test, which Robbins failed. Id. Officers then arrested Robbins and obtained a
blood sample that tested positive for methamphetamine, amphetamine, marijuana, and
marijuana metabolites. Id. Robbins received multiple DUI charges; an (A)(1) charge for
being actually impaired, and an (A)(3) charge for having prohibited drugs in his system
while driving. Id. The lower court denied Robbins’ attempt to submit his AMMA card into
evidence to establish an affirmative defense to both charges. Id. at *1–2. On appeal, the
court (correctly) asserted that the AMMA does not provide an affirmative defense to an
(A)(1) charge, which is based upon actual impairment. Id. at *3. The court did, however,
conclude that the AMMA card should have been allowed into evidence to establish an
affirmative defense to the (A)(3) charge. Id. Ultimately the court concluded that the error
was harmless, however, since the presence of amphetamine and methamphetamine in
Robbins’ blood was sufficient for conviction under (A)(3), regardless of the presence of
marijuana. Id. at *4.
128 See ARIZ. REV. STAT. § 28-1381(A)(3) (West 2016); Dobson, 361 P.3d at 378.
129 The largest obstacle to presenting evidence of marijuana’s impairing effects
and its variability among individual users, particularly chronic users such as medical
patients, is marijuana’s continued listing as a Schedule I drug. By categorizing
marijuana as a Schedule I drug (a drug that has no accepted medicinal value) the
federal government has effectively shutdown much of the research that would be
needed for medical marijuana patients to present a good, science-based, affirmative
defense. See Drug Scheduling, DRUG ENF’T ADMIN., https://www.dea.gov/druginfo/ds.s
126

127
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While a per se DUI prohibition on marijuana lacks
scientific sense in that it is likely to be over-inclusive in a state
that sanctions medical marijuana, the lack of a numerical
threshold for THC blood concentration—as exists in other
states—prevents the law from being underinclusive as well.130
This is a problem confronted by states that have started to adopt
numerical limits for THC blood concentrations similar to the
way in which alcohol DUIs have been regulated. To gain a
better understanding of these numerical THC thresholds, it is
necessary to venture from the deserts of Arizona to the Rocky
Mountains of Colorado, where the progressive push to legalize
marijuana has been strongest.
B.

Colorado

For the past decade, Colorado has led the United States in
instituting progressive marijuana reforms.131 In 1998, Colorado
voters approved an amendment to the state constitution—with a
54% majority—to legalize medical marijuana.132 The medical
marijuana program remained relatively small until the mid-aughts
when state courts increasingly began to interpret the amendment’s
language broadly.133 Bolstered by the election of President
Obama—who advised the Department of Justice to make the
federal prosecution of state-authorized medical marijuana
programs among its lowest priorities—the Colorado marijuana
revolution began, and dispensaries boomed into business across
the state.134 Colorado voters made the state the first to legalize
the recreational use of marijuana after passing Amendment 64
with 55% of the vote in 2012.135 As a result, Colorado has perhaps

html [https://perma.cc/C9C7-S9XR] (“Schedule I drugs, substances, or chemicals are defined
as drugs with no currently accepted medical use and a high potential for abuse.”).
130 In a recent report on the marijuana DUIs, the American Automobile
Association (AAA) concluded that “a quantitative threshold for per se laws for THC
following cannabis use cannot be scientifically supported.” BARRY LOGAN ET AL., AAA
FOUND. FOR TRAFFIC SAFETY, AN EVALUATION OF DATA FROM DRIVERS ARRESTED FOR
DRIVING UNDER THE INFLUENCE IN RELATION TO PER SE LIMITS FOR CANNABIS 3 (2016).
Out of the 11,328 DUI cases studied, that involved the presence of marijuana, “58.3
percent of drivers had THC concentrations [of] less than 5 ng/mL.” Id. at 21. Thus,
most drivers with marijuana in their system—regardless of impairment—would be
below the thresholds set in states like Colorado.
131 See generally Tiftickjian, History of Marijuana Legislation in Colorado, supra
note 10 (Jay Tiftickjian has compiled an entire book on the evolution of Colorado’s
increasingly progressive marijuana laws.).
132 Id. at 2–3.
133 Id. at 3.
134 Id.
135 Id.
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the highest number of marijuana regulations in the country—
including marijuana DUI laws.
Colorado implemented a relatively novel marijuana DUI
standard that is based upon a driver’s blood concentration of
THC, in lieu of the per se standards set by states like Arizona.136
Pursuant to C.R.S. section 42-4-1301(6)(a)(IV):
In any prosecution for DUI or DWAI, the defendant’s BAC or drug
content at the time of the commission of the alleged offense . . . gives
rise to the following presumptions or inferences:

....
If at such time the driver’s blood contained five nanograms or
more of delta 9-tetrahydrocannabinol [THC] per milliliter in whole
blood, as shown by analysis of the defendant’s blood, such fact gives
rise to a permissible inference that the defendant was under the
influence of one or more drugs.137

The Colorado marijuana DUI statute is important for two
reasons: it contains a “permissible inference” clause, and it sets a
numerical threshold to establish such a “permissible inference.”138
While a per se DUI regime—such as the one employed in
Arizona—creates a presumption of guilt if the defendant tests
positive for any level of THC,139 Colorado has adapted a
“permissible inference” standard, whereby the presence of THC
levels at, or above, the numerical threshold triggers an inference
of guilt rather than a complete presumption.140 It is a subtle yet
important distinction in the law since a marijuana DUI case is
“almost certainly more open to attack than presumptive alcohol
limits, if for no other reason than the relative lack of research
on the actual effects of THC levels on driving, as well as
potential variations in tolerance levels and previous use.”141 By
enacting a scheme that gives rise to a lesser “permissible
inference” of guilt—compared to a “presumption” of guilt—the
legislature implicitly accepts that the correlation between THC
blood concentration and driving impairment is much more
tenuous than the relationship between BAC and driving
impairment. The permissible inference standard should still be
lauded as a shift away from a draconian per se regime.
136 See Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 87.
137 COLO. REV. STAT. § 42-4-1301(6)(a)(IV) (2016) (emphasis added).
138 See id.
139 See Dobson v. McClennen, 361 P.3d 374, 375, 378 (Ariz. 2015).
140 Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 89.
141 Id.
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Missing in Colorado’s five-nanogram permissible inference
limit is any guidance regarding how to treat drivers who test
positive for THC, but test under the five-nanogram threshold.142
There is no presumption of innocence if a driver tests positive for
THC but below the five-nanogram threshold.143 While there is
still no widely accepted numerical threshold for marijuana
impairment, allowing a presumption of innocence for those
testing under a certain THC level is likely to be under-inclusive,
since the novice marijuana user could still be impaired at such a
level.144 Given the wide variation among individual tolerance
levels for marijuana impairment, any numerical threshold for
even a “permissible inference” of impairment runs counter to
the established science, and fails to fully consider actual
driving impairment. While exact numerical thresholds are
inherently problematic, Colorado has otherwise managed to
craft a marijuana DUI statute that is, at least, less draconian
than Arizona’s.
1. Colorado’s Marijuana DUI Statute
i. No Presumption of Innocence
While the absence of a presumption of innocence for
positive THC tests below the five-nanogram level has its pros
and cons, all numerical thresholds (for either guilt or innocence)
are inherently suspect. One of the downsides of not having any
presumption of innocence for even low THC levels is that
marijuana impairment varies considerably among individuals.
This is particularly true with chronic users and medical patients
who may have adapted learned behaviors to counteract their
impairment,145 and who may, even during periods of abstinence,
continue to test positive for low levels of THC. Additionally,
while it is well-known that heavy drinkers can build some
degree of tolerance to alcohol, alcohol tolerance with regard to its
impact on driving differs considerably from marijuana tolerance,
both in adapted learned behaviors and actual impairment.146
See COLO. REV. STAT. § 42-4-1301 (2016).
Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 87.
144 See Johannes G. Ramaekers et al., Tolerance and Cross-Tolerance to
Neurocognitive Effects of THC and Alcohol in Heavy Cannabis Users, 214
PSYCHOPHARMACOLOGY 391, 398 (2011).
145 See Grotenhermen et al., supra note 42, at 1913.
146 See Sewell et al., supra note 44, at 190. The effects of marijuana tolerance
vary considerably among individuals when compared to the effects of alcohol tolerance
in alcoholics and heavy drinkers. See id. Additionally, the fact that marijuana-impaired
drivers tend to overestimate their level of impairment while alcohol-impaired drivers
142

143
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While alcohol has predictable impairing effects on all people
once a certain BAC level is achieved,147 the same does not
necessarily hold true for frequent marijuana users. Medical
marijuana patients and chronic recreational users might
always be above the five-nanogram threshold, but fail to
experience any impairing psychomotor behavior. These two
classes of users, medical marijuana patients and chronic
recreational users, will, without a presumption of innocence
threshold, almost always sustain “guilty” levels of THC in their
systems. This is because
experienced cannabis consumers—such as the majority of Colorado’s
qualified medical cannabis patients and many of the state’s
recreational consumers—become tolerant to the substance’s
behavioral effects. These subjects also retain trace concentrations of
THC for extended periods of time well beyond the duration of
impairment, making them potentially vulnerable to inappropriate
prosecution and conviction under Colorado’s DUI THC inference.148

Such classes of users are obviously at a much-heightened risk
of being prosecuted because of their persistently high THC blood
concentrations.149 Medical marijuana patients and chronic
recreational users therefore face a significant issue with regard
to notice because such classes of users will likely never be able
to estimate their THC blood concentration levels given the
chronicity of their use. The absence of a presumption of innocence
threshold thus places medical marijuana users and chronic
recreational users in perpetual jeopardy of being prosecuted
irrespective of actual impairment.150 While the lack of a
presumption of innocence level places the burden on chronic
marijuana users to prove their innocence by other means (such
as a lack of actual impairment), it effectively prevents another
class of marijuana users from evading the law altogether.
Though the lack of a presumption of innocence for
certain levels of THC has its clear downside with regard to
particular classes of chronic users, it has a legitimate penological
purpose with regard to another class of marijuana users. Those
tend to underestimate their level of impairment makes driving while impaired by
marijuana significantly safer than drunk-driving, assuming the two substances are not
combined. See id.
147 See supra Section I.A.
148 Paul Armentano, Are THC Concentrations Appropriate for Presuming
Psychomotor Impairment?, in MEDICOLEGAL ASPECTS OF MARIJUANA: COLORADO
EDITION, supra note 10, at 131, 134.
149 See id.
150 See Eef L. Theunissen et al., Neurophysiological Functioning of Occasional
and Heavy Cannabis Users During THC Intoxication, 220 PSYCHOPHARMACOLOGY 341,
349 (2012).
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who do not ingest marijuana—or only occasionally use the
psychoactive—could theoretically become very impaired from a
single “hit” of a marijuana cigarette without going over the
five-nanogram threshold.151 Thus, the novice user who gets into
a car after the first “hit” of marijuana might have a THC level
below five-nanograms but still be impaired, while the medical
marijuana patient who has not used marijuana in days could
find himself above the five-nanogram threshold despite lacking
any impairing effects.152 It would be illogical for the impaired
novice user to bypass the DUI laws because he decided to
experiment with the drug before getting behind the wheel,
while the experienced medical marijuana smoker who has not
used the drug in hours, or days, gets prosecuted despite a lack
of impairment. The science indicates that the experienced
marijuana user will not feel the same levels of impairment as a
novice user despite significantly higher THC concentrations.153
Infrequent marijuana users are more sensitive to lower levels
of THC as it relates to performance impairment.154 Additionally,
there is science that indicates that some impairment is possible
from as little as one or two nanograms of THC in whole blood.155
The lack of a presumption of innocence for any level of THC
corresponds to the scientific reality that certain individuals—
particularly novice users—may still experience psychomotor
impairment at levels under a five-nanogram threshold. The
Colorado statute’s lack of a presumption of innocence at any
level aligns with the legitimate penological goal of keeping
impaired drivers off the road, since such impairment can
occur—particularly among novice users—at relatively low THC
blood concentrations.
ii. The Numerical Permissible Inference Threshold
Since the science shows such wide variability in marijuana
impairment among individuals—particularly depending upon
chronicity of use—the legitimacy of a numerical “permissible
inference” THC threshold is inherently dubious. Colorado’s
151 See W.M. Bosker et al., A Placebo-Controlled Study to Assess Standardized
Field Sobriety Tests Performance During Alcohol and Cannabis Intoxication in Heavy
Cannabis Users and Accuracy of Point of Collection Testing Devices for Detecting THC
in Oral Fluid, 223 PSYCHOPHARMACOLOGY 439, 444–45 (2012) (noting the difference in
impairing effects of marijuana between chronic users and less frequent users).
152 See id.
153 See Theunissen et al., supra note 150, at 342.
154 See Johannes G. Ramaekers et al., Tolerance and Cross-Tolerance to
Neurocognitive Effects of THC and Alcohol in Heavy Cannabis Users, 214
PSYCHOPHARMACOLOGY 391, 398 (2011).
155 See Karschner et al., supra note 49, at 2045.
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statute creates a permissible inference of being under the
influence of marijuana for THC blood concentrations at, or above,
the five-nanogram limit.156 Therefore, a Colorado jury is permitted
to infer a finding that a driver was under the influence of
marijuana when tests show THC at, or above, the five-nanogram
threshold.157 While a permissible inference is not quite as strong
as a presumption of guilt—such as the Arizona per se DUI
statute—it still remains unlikely that a defendant will be
acquitted for a DUI under Colorado’s law.158 Thus, “[a] jury, if it is
so-inclined, may convict a defendant of being under the influence
of marijuana simply upon proof that the five-nanogram threshold
was satisfied.”159 This type of inference is more “open to attack”
than a per se prohibition or a presumption of guilt threshold “if
for no other reason than the relative lack of research on the
actual effects of THC levels on driving, as well as potential
variations in tolerance levels and previous use.”160 Yet, with more
states legalizing the medical or recreational use of marijuana—
and the strong push for drug reform from the progressive wing of
the Democratic Party161—additional research in the near future
could theoretically make numerical thresholds more precise (like
BAC), and thus more open to attack in court. Currently though,
there is only limited research in the area of marijuana-impaired
driving, with what little existing research consistently showing
the variable nature of the drug upon different individuals.
Therefore, precise thresholds make little scientific sense if the
standard for a DUI is to be actual driving impairment.162
Research into the impairing effects of marijuana on
drivers is essential if any THC threshold statute is going to
contain a permissible inference clause.163 Yet the law has
imposed a five-nanogram threshold without a robust foundation
in actual science.164 Without a substantial scientific basis “it may
be argued that Colorado’s permissible inference statute is an
unscientific and inadvisable public policy response to behavior
COLO. REV. STAT. § 42-4-1301(6)(a)(IV) (2016).
See id.
158 Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 87.
159 Id. at 89.
160 Id.
161 See John Wagner & Christopher Ingraham, Sanders Proposes Nixing
Marijuana from Federal List of Dangerous Drugs, WASH. POST (Oct. 28, 2015), https://
www.washingtonpost.com/politics/sanders-will-propose-nixing-marijuana-from-federallist-of-dangerous-drugs/2015/10/28/be8c3adc-7da2-11e5-b575-d8dcfedb4ea1_story.html
[https://perma.cc/K9WA-GRYX].
162 See Armentano, supra note 148, at 132.
163 See id. at 134.
164 See id.
156
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that is already sufficiently addressed by existing traffic safety
laws, which already criminally prohibit driving while impaired
by drugs, including cannabis.”165 Despite increasing acceptance
of progressive marijuana laws and the various regulations that
come with it, such as DUI laws, “it remains far from established
that the identification of either THC or the carboxy THC
metabolite at specific levels may be consistently correlated with
behavioral impairment.”166 As long as science can find no direct
correlation between increased blood THC concentrations and
driving impairment,167 then any numerical standard starts to
become suspect and illegitimate under a jurisprudence that
should be based upon actual impairment and dangerousness.
2. The Colorado Court’s Response to the Marijuana DUI
Statute
Despite the murky scientific waters the Colorado
legislature has waded into, the federal district court seemed
reluctant to challenge the five-nanogram limit as being
unconstitutionally vague in Baker v. State.168 While the plaintiff
in Baker brought a litany of claims in an attempt to challenge
Colorado’s marijuana DUI statute,169 only the Fourteenth
Amendment claim seemed to hold any water170—though not in
the eyes of the district court.171 The court made clear that the
plaintiff’s reliance on certain statistics for the Fourteenth
Amendment claim was unpersuasive, noting that
[w]hile a correlation between an increase in cannabis use and a
decline in automobile accidents might exist, the relevant inquiry is
whether driving under the influence increases one’s probability of
causing an automobile accident. The fact that cannabis use has
increased while automobile accidents have decreased does not
unequivocally defeat causation.172

Although the accident statistics used to substantiate plaintiff’s
claim that the marijuana DUI statute was unconstitutionally
vague were irrelevant, as the court explicitly noted, the legal
Id. (emphasis added).
Id. at 131–32.
167 Rebecca L. Hartman & Marilyn A. Huestis, Cannabis Effects on Driving
Skills, 59 CLINICAL CHEMISTRY 1, 11 (2013).
168 See Baker v. State, No. 13-cv-01334-PAB-KLM, 2014 WL 624342, at *12
(D. Colo. Feb. 18, 2014) (recommendation of U.S. Magistrate Judge).
169 See id. at *3–4 (The plaintiff also included a First Amendment religious
freedom claim, a Fourth Amendment search and seizure claim, and a Sixth Amendment
confrontation clause claim.).
170 See id. at *4.
171 Id. at *11–12.
172 Id. at *12 (recommendation of U.S. Magistrate Judge).
165
166
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underpinning of the claim was not without merit should better
scientific evidence come to light. Whereas a per se BAC threshold
can pass muster under a vagueness claim because of the strong
correlation between BAC and alcohol impairment, the same
correlation does not exist between THC and marijuana
impairment. The court asserted, however, that since “the [fivenanogram] statutory limit provides sufficient guidance as to what
constitutes driving ‘under the influence’ and fair notice of the
prohibited conduct, Plaintiff fails to sufficiently allege that the
statute is unconstitutionally vague.”173 The court seems
unconcerned with regard to the inherently problematic nature of
proper notice when one considers that most medical marijuana
users and chronic recreational smokers may always be over the
THC limit without a simple way of knowing.174 It is perhaps this
claim—that the five-nanogram threshold is unconstitutionally
vague—that opens the door for science to explain why any
numerical threshold could be considered unconstitutionally vague.
Ultimately, Colorado’s DUI marijuana statute, and the
limited case law that has developed around it, provide at least
a baseline for what a relatively progressive marijuana DUI
statute may look like. It is true that Colorado’s “unique traffic
safety measure risks inappropriately convicting unimpaired
subjects of traffic safety violations, including and most especially
legally qualified patients who may have previously consumed
medicinal cannabis in the privacy of their own home some days
earlier.”175 It is equally true, however, that Colorado’s statute
does at least something to provide protections for medical and
chronic recreational users by adopting a legislative scheme
without any per se threshold—and a lower standard of
permissible inference instead. In light of the recent experiments
in marijuana DUI legislation in states with established medical
or recreational marijuana regimes, it makes sense to turn to a
state in the process of implementing its first medical marijuana
program—New York.176

Id.
The only widely used way of accurately detecting THC is via a blood
sample which the typical layperson will not have easy and abundant access to. See
supra Section I.B (discussing the problems associated with testing for marijuana).
175 Armentano, supra note 148, at 134.
176 See Madison Margolin, Here’s Why Doctors Are Still Skeptical About New
York’s Medical Marijuana Law, VILLAGE VOICE (Oct. 23, 2015), http://www.villagevoice.
com/news/heres-why-doctors-are-still-skeptical-about-new-yorks-medical-marijuana-law7811336 [https://perma.cc/SY7B-YL3P].
173
174
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New York

New York’s long slog toward implementing a medical
marijuana program has been in the works for decades, but only
started to gain real momentum when State Assemblyman
Richard Gottfried began introducing such legislation as the
Compassionate Care Act back in 1997.177 By the summer of
2014, and after numerous failed attempts in the legislature,
Assemblyman Gottfried was able to convince Governor Cuomo
to sign a much narrower and more restrictive version of the
Compassionate Care Act.178 While the legislation officially went
into effect on January 1, 2016, the law is considered so
restrictive as to be hollow in its actual impact on potential
medical marijuana patients.179 The statutory language of the
New York State Compassionate Care Act, however, alludes to
its own possible expansion to cover an increasing number of
relatively less severe conditions and illnesses.180 Unlike other
states, such as Colorado, New York has not developed any new
legislation to address marijuana DUIs, specifically, as the state
begins to implement its medical program. New York thus
provides a relatively blank slate upon which to suggest
statutory regulations for marijuana DUI laws and potential
protections for medical marijuana patients that can serve as a
model DUI regime based upon actual driving impairment.
New York’s current DUI laws do not make reference to
any specific drug other than alcohol,181 rather, the single
statute defines various levels of alcohol-related DWIs without
any reference to marijuana. The law states, in pertinent part,
that “[n]o person shall operate a motor vehicle while the person’s
ability to operate such a motor vehicle is impaired by the use of
a drug as defined in this chapter.”182 The term “drug” is defined
by the statute as any drug listed in section 3306 of the Public
Health Law which prohibits various controlled substances—
177 See Madison Margolin, Why the Architect of New York’s Medical Marijuana
Law Is Already Trying to Change It, VILLAGE VOICE (Nov. 3, 2015), http://www.village
voice.com/news/why-the-architect-of-new-yorks-medical-marijuana-law-is-already-tryingto-change-it-7864748 [https://perma.cc/R4T4-L4XB].
178 See id. Governor Cuomo still only reluctantly signed the bill after severely
restricting the legislation by limiting the number of dispensaries in the state as well as
the types of diseases and conditions that would make a patient eligible for marijuana
treatment. Id.
179 See id.
180 See N.Y. PUB. HEALTH LAW § 3360(7)(ii)(b) (McKinney 2016) (“No later than
eighteen months from the effective date of this section, the commissioner shall determine
whether to add the following serious conditions: Alzheimer’s, muscular dystrophy,
dystonia, post-traumatic stress disorder and rheumatoid arthritis.”).
181 See N.Y. VEH. & TRAF. LAW § 1192 (McKinney 2016).
182 Id. § 1192(4).
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including marijuana.183 There is nothing indicating that New
York intends to change marijuana’s designation in its prohibited
substances list, and there is also a legitimate reason why New
York need not do so to enforce a marijuana DUI policy that
protects medical marijuana patients while still criminalizing
impaired drivers.
New York’s facially simplistic statutory language for
criminalizing drug-impaired driving—with some additional
safeguards for medical marijuana patients—has the potential
to be a relatively ideal marijuana DUI law. New York’s
impairment statute neither includes any per se restrictions on
drug quantities or metabolites, nor imposes a numerical threshold
for either a presumption of impairment or a permissible inference
of such.184 The statute does not discriminate among various drugs
either, and simply refers to any drug listed in the health code’s
controlled substances list.185 This statutory structure is very
much in line with a legal theory based upon actual impairment,
since it does not attempt to divine numerical limits for impairment
based upon murky science, but rather maintains a subjective
standard of impairment because specific drug concentrations do not
correlate strictly with driving impairment.186
New York lawmakers realized the potential issue of
measuring driving impairment based on drug concentrations as
early as 1985.187 An interim report on drug-impaired driving by
the legislature found several major problem areas regarding
drugged driving, including in pertinent part, “the inability to
state specifically that a defined level of a specific drug is
impairing.”188 Viewed in light of such a report, New York’s
drugged driving statute is astute in its simplicity. By creating
statutory language without numerical thresholds for drug
impairment, New York lawmakers have inadvertently created a
statutory DUI regime based upon impairment and dangerousness,
which has gone unchanged even in light of medical marijuana’s
implementation. Lawmakers in New York would be wise to let
the existing laws stand as is, since such laws rely entirely on
actual driving impairment with regard to drugs like marijuana.
Safeguards, such as the affirmative defense available in Arizona’s
AMMA,189 as well as some minor policy changes, would go a long
See id. § 1192.
See id. § 1192(4).
185 See id.
186 See Roth, supra note 16, at 897.
187 INTERIM REPORT: THE DRUG IMPAIRED DRIVER, supra note 90, at 28.
188 Id.
189 ARIZ. REV. STAT. § 36-2802(D) (West 2016); see Dobson v. McClennen, 361
P.3d 374, 378 (Ariz. 2015).
183
184
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way in creating a truly ideal marijuana DUI policy. The following
part will use New York’s simplistic DUI laws as a foundation
upon which a scientifically legitimate marijuana DUI policy can
be built.
III.

A MODEL FOR STATES: BUILDING ON NEW YORK’S DUI
LAW

If marijuana is too unique, and thus overly problematic,
for the creation of a THC threshold that accurately judges
impairment, then a subjective impairment standard may be the
best approach, rather than a standard such as Arizona’s, which
is designed to more easily obtain DUI convictions.190 Instead of
creating arbitrary—and potentially problematic—numerical
thresholds for THC blood concentrations, lawmakers should
not settle for an illogical arithmetic standard in our justice
system for the sake of easily securing more convictions.191
Rather, “[t]he answer should be to settle for an imperfect
subjective impairment standard for criminal DUI marijuana
laws.”192 Lawmakers should, therefore, build off of—and
strengthen—New York’s subjective impairment standard by
adding statutory protections for medical marijuana patients
and by implementing simple policy methods—such as the use
of DREs and body-cameras—to curb the large degree of police
discretion inherent in a subjective impairment standard.
A.

Policy Considerations

The International Association of Chiefs of Police (IACP)
has established a national standard for training and certifying
officers to conduct drug recognition evaluations (DRE) in
suspected drugged driving cases.193 Officers qualified to perform
DREs194 will have to be considered experts by the court to
testify as to their conclusions from a drug recognition
evaluation,195 and courts should become increasingly willing to
admit them as such, at least for this limited purpose. The DRE
consists of a twelve-step process that includes: a breath alcohol
Roth, supra note 16, at 917.
Id.
192 Id.
193 Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 98.
194 The acronym DRE is often used interchangeably with “drug recognition
expert” as well as “drug recognition evaluation.”
195 Tiftickjian, Colorado’s Alcohol & Drug-Related Driving Offenses, supra
note 94, at 98.
190
191
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test, an interview of the arresting officer, preliminary
examination and pulse rate, an eye examination, divided
attention psychophysical testing, vital sign testing, dark room
examinations, muscle tone examinations, injection site
examination, questioning regarding drug use, analysis of the
totality of circumstances, and finally, a conclusion as to whether
the suspect should undergo a toxicology exam.196 New York’s 1985
report on drugged driving even states that
[t]he [DRE] officers are qualified to take blood pressure readings and
examine the eyes of drivers. For marijuana, officers look for
symptoms such as high blood pressure and a rapid pulse rate. The
chief technique they use, however, is the Horizontal Gaze
Nystagmus test. . . . Specific coordination tests also are used since
divided attention impairment occurs with marijuana use . . . .197

With an increasing number of states legalizing the use of
marijuana, it is logical to suggest that police officers engaged in
enforcing traffic laws should have increased training to identify
marijuana impairment.
Given a subjective impairment standard that will
depend heavily on police discretion, the importance of
increasing the number of qualified DRE officers available on
the road is imperative for enforcement purposes. Standardized
field sobriety tests (SFST), which all police officers are qualified
to perform, have proven to be ineffective in indicating the
probability of impairment in marijuana-exposed individuals.198
DREs, on the other hand, have proven to be more useful in
determining drug impairment than urine or blood tests, and as
a result, drug recognition experts are increasingly used across
the country.199 According to law enforcement officials in Ohio,
for instance, DRE officers “have an 86 percent accuracy rate
when their assessments are compared to the [actual] results of
blood and urine tests.”200 State funds thus should be allocated
to expanding DRE programs, and studies should be initiated to
adequately validate the legitimacy and accuracy of DREs.201

Id. at 99–100.
INTERIM REPORT: THE DRUG IMPAIRED DRIVER, supra note 90, at 22.
198 See John P. Bederka, Jr. & Warren Cooper, Under the Influence of
Marijuana, in MEDICOLEGAL ASPECTS OF MARIJUANA: COLORADO EDITION, supra note
10, at 183.
199 See Allison Manning, Going Beyond Sobriety Tests, Officers Learning to
Gauge Drug Use, COLUMBUS DISPATCH (May 24, 2013), http://www.dispatch.com/
content/stories/local/2013/05/24/officers-learningto-gauge-drug-use.html [https://perma.
cc/7G76-MTGE].
200 Id.
201 Roth, supra note 16, at 845–46.
196
197

274

BROOKLYN LAW REVIEW

[Vol. 82:1

Finally, given an increased reliance on police discretion
under a subjective impairment standard, the need for concrete
evidence corroborating police or DRE officer testimony would
be essential to curb any abuses of power and to provide
additional support for convictions (or acquittals). States should
increase resources “for dashboard and body-worn cameras,
which could be used to corroborate” DRE officer testimony and
analyze physical indications of marijuana impairment.202 Policeworn body cameras easily attach to an officer’s shirt and can
record all interactions with potentially impaired drivers203—
similar to the dashboard cameras in police vehicles that have
been used for years. Increased use of police body and dashboard
cameras has already gained traction among the public as a
result of the recent media focus on the excessive use of force by
police.204 With public sentiment focused intently on the use of
police body cameras to curb the excessive use of force, there is
already a strong push toward increasing the use of such
devices.205 Increasing the accuracy of DUI convictions via the
use of police body and dashboard cameras would merely be
harnessing already existing and increasingly prevalent police
technology. This is another mode—and another reason—in
which such technology can increase public safety while serving
a state’s penological goals.
B.

Statutory Considerations

While New York’s DUI statute wisely focuses on the issue
of impairment as opposed to numerical THC blood concentration
thresholds, it still fails to provide necessary protections for
medical marijuana patients who drive, such as an affirmative
Id.
See Eric Markowitz, The LAPD Plans to Buy 7,000 Police Body Cameras, but
Administrators Balk over Price and Critics Cry Foul, INT’L BUS. TIMES (Jan. 15, 2016),
http://www.ibtimes.com/lapd-plans-buy-7000-police-body-cameras-administrators-balkover-price-critics-cry-2265613 [https://perma.cc/P6F9-CA2Y].
204 See, e.g., David Feige, Brutal Reality, SLATE (Apr. 10, 2015,), http://www.
slate.com/articles/news_and_politics/jurisprudence/2015/04/police_body_cameras_cops_
commit_less_violence_and_complaints_are_real.html [https://perma.cc/7XMY-KDVK].
205 The recent epidemic of highly publicized (and video recorded) police shootings
of unarmed black men has motivated lawmakers to institute various police-policy
reforms—including the use of body-worn cameras. See id. While such shootings are not
new, the pervasiveness of video-recording technology, as well as police-worn body
cameras, have propelled such incidents into the public spotlight. Some of the most highly
publicized victims of the use of force by police include: Keith Lamont Scott, Terence
Crutcher, Alton Sterling, Freddie Gray, Walter Scott, Tamir Rice, and Michael Brown.
Damien Cave & Rochelle Oliver, The Raw Videos That Have Sparked Outrage over Police
Treatment of Blacks, N.Y. TIMES (Oct. 4, 2016), http://www.nytimes.com/interactive/2015/
07/30/us/police-videos-race.html [https://perma.cc/38RR-PQT5].
202
203
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defense. Nothing in New York’s Compassionate Care Act creates,
or even alludes to, additional protections for medical marijuana
patients who are likely to be behind the wheel at some point.206
Lawmakers should consider whether additional protections are
needed for medical marijuana patients, as well as patients being
prescribed Xanax, Valium, or any other potentially impairing
drug listed among New York’s controlled substances.207 If
lawmakers create regulations based upon a subjective standard of
impairment, does it really matter what substance is causing the
impaired driving? In theory it should not matter; impaired
driving due to a controlled substance is still a DUI regardless of
the drug used.208 In practice, however, it does matter.
Consider the case of People v. Morel in which Augustin
Morel was charged with a marijuana DUI in New York.209 The
only piece of evidence used against Mr. Morel was the accusatory
instrument, sworn to by the arresting officer, which read in
pertinent part:
I observed the defendant driving a car at the above-mentioned
location I know the defendant was under the influence of drugs
because I smelled an odor of marijuana coming from the defendant’s
clothing, I observed that the defendant had watery and bloodshot
eyes, and I observed that the defendant had ash containing
marijuana on his pants.210

The defense argued, to no avail, that the complaint contained
no allegations that the defendant was driving erratically or
dangerously, such that would have demonstrated that he may
have been impaired.211 Defense counsel argued, and the court
concurred, that “the complaint contains no allegations that
Defendant’s driving was erratic, reckless or otherwise unlawful
and dangerous to demonstrate he was not operating the car
reasonably and prudently.”212 The court held that though the
complaint was confined to “bare-bone allegations with respect
to Defendant’s driving, the Appellate Division, First Department
has held that not all classic symptoms of impairment or
intoxication need be exhibited to establish that the defendant
was incapable of operating the vehicle as a reasonable and
prudent driver.”213 Mr. Morel was charged not because he was
See N.Y. PUB. HEALTH LAW § 3362 (McKinney 2016).
See id. § 3306.
208 See N.Y. VEH. & TRAF. LAW § 1192(4).
209 People v. Morel, No. 2015NY010820, 2015 WL 5038282, at *1 (Crim. Ct.
N.Y. Cty. Aug. 25, 2015).
210 Id. at *1–2.
211 Id. at *2.
212 Id.
213 Id.
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observed driving dangerously, recklessly, or while impaired, but
rather because he had admitted to the arresting officer to having
recently smoked marijuana.214 This type of conviction may be
tolerable in a prohibitionist regime, whereby the act of smoking
itself is sufficiently morally blameworthy, but this conviction
would be inherently suspect in a jurisdiction that authorizes
certain levels of marijuana use.
If Mr. Morel had been a medical marijuana patient,
however, lawmakers might begin to think differently about
whether a person in his situation should have been convicted of
a marijuana DUI. What makes marijuana different than other
controlled substances—with regard to arrests and convictions—
goes beyond the simple fact that marijuana’s odor is easily
detected or that a common side-effect is blood-shot eyes. The fact
is that marijuana remains a highly stigmatized substance, both
for law enforcement that have used it as a tool for convictions
during their decades long War on Drugs,215 as well as for
medical marijuana patients themselves.216 As long as a stigma
continues to surround marijuana use, affording medical marijuana
patients additional statutory protections from marijuana DUI laws
is necessary.
C.

How to Best Protect Legal Marijuana Users

New York’s DUI statute, as well as other states’ statutes,
should include additional protections for medical marijuana
patients in the form of an explicit affirmative defense similar to
the one created by the AMMA as interpreted by the most recent
214 Id. (The arresting officer also noted that the defendant smelled of
marijuana odor.).
215 See generally MICHELLE ALEXANDER, THE NEW JIM CROW (rev. ed. 2012)
(Michelle Alexander’s seminal work is perhaps one of the best pieces of writing describing
mass incarceration, the War on Drugs, and the role of systemic racism in perpetuating
the two. As Alexander succinctly explains: “More than 2 million people found themselves
behind bars at the turn of the twenty-first century, and millions more were relegated to
the margins of mainstream society, banished to a political and social space not unlike Jim
Crow, where discrimination in employment, housing, and access to education was
perfectly legal, and where they could be denied the right to vote. The system functioned
relatively automatically, and the prevailing system of racial meanings, identities, and
ideologies already seemed natural. Ninety percent of those admitted to prison for drug
offenses in many states were black or Latino, yet the mass incarceration of communities
of color was explained in race-neutral terms, an adaptation to the needs and demands of
the current political climate. The New Jim Crow was born.” Id. at 58.).
216 See Satterlund et al., supra note 23, at 15 (“Furthermore, marijuana use is
generally criminalized on the one hand, yet increasingly normalized on the other. This
contradiction has further ambiguated the social status of marijuana and marijuana
consumers. Further complicating matters, state recognition of marijuana as a recreational
drug may undo the gains of the hard-fought battles for recognition of marijuana as a
medicinal substance, undermining the legitimacy of ‘cannabis’ and marijuana ‘patients,’ and
reducing all consumers to ‘drug users’ again.” (internal citation omitted)).

2016]

POTHOLES

277

Dobson decision.217 Such a defense would allow the prosecution
to not only enter into evidence any signs of driving
impairment—including lab test results for THC—but allow
medical marijuana patients to rebut any claim that certain
THC levels created actual impairment. This type of protection
would be most useful in states that do decide to create per se or
permissible inference thresholds for THC concentration. Evidence
that a driver’s blood contained THC in excess of a statutorily
defined numerical threshold would be rebutted by evidence of a
driver’s medical marijuana ID or prescription, the prescribing
physician’s testimony,218 and relevant expert testimony regarding
THC tolerance and its impact on driving impairment. While in
the previously described case Mr. Morel was not a medical
marijuana patient,219 had he been a legal patient with an
affirmative defense available to him, he would have been able to
present evidence showing that despite his relatively recent use,
his driving ability remained unimpaired. Mr. Morel would
submit his medical marijuana ID into evidence and his
prescribing physician would be able to testify as to Mr. Morel’s
condition, need, and subsequent tolerance to the impairing
effects of THC. Expert witnesses could be called upon to testify
that Mr. Morel’s THC test is indicative of only prior, legal drug
use and is thus not indicative of driving impairment at the
time of arrest. The burden would then shift to the prosecution
to present evidence, such as DRE officer testimony and body or
dashboard camera footage, showing that Mr. Morel’s driving was
impaired despite his otherwise legal drug use. Such an
affirmative defense would allow a medical marijuana defendant
to shift the burden of proof to the prosecution to provide
evidence, beyond THC blood tests, that shows that the driver
was actually impaired by marijuana. Yet, in states that allow for
both the medical and recreational use of marijuana, should only
medical patients be afforded such an affirmative defense?
Given a legal theory based upon actual impairment and
dangerousness—a theory in which New York’s DUI regime
appears to be grounded—little separates the medical marijuana
patient from the chronic recreational user in states that have
See Dobson v. McClennen, 361 P.3d 374, 378 (Ariz. 2015).
This could become increasingly pertinent if future science enables doctors to
give more precise dosing recommendations. The degree to which future science will
enable precision in dosing remains unclear as marijuana research has remained stunted.
See Susan Haigh, This New England State Wants Researchers to Begin Studying Its Medical
Marijuana, THE CANNABIST (Oct. 3, 2016), http://www.thecannabist.co/2016/10/03/
connecticut-medical-marijuana-research/64462/ [https://perma.cc/5YA5-EHTW].
219 This case took place before implementation of New York’s Compassionate
Care Act.
217
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sanctioned both medical and recreational marijuana. Marijuana
use is equally permissible for both individuals, yet it would seem
counterintuitive to provide only the medical marijuana patient
an affirmative defense. Indeed, providing medical marijuana
patients such an affirmative defense without allowing chronic
recreational users a similar defense would undermine the
purpose of the affirmative defense itself, specifically, the ability
to challenge the prosecution’s reliance on a high THC blood
concentration as the case-in-chief for attaining a DUI conviction.
Further, the explicit statutory affirmative defense for medical
marijuana users could create equal protection issues if such a
defense is not available to all legal marijuana users.220
Lawmakers should therefore consider the merits of expanding
such an affirmative defense to all legal marijuana users.
An affirmative defense should be provided to chronic
recreational marijuana users in states that sanction both medical
and recreational use. Just as it makes little scientific or penological
sense to convict an unimpaired medical marijuana patient for
driving over the statutory THC threshold, it makes little scientific
or penological sense to convict the chronic recreational user in the
same situation. If non-medical marijuana use is sanctioned—and
thus no longer morally blameworthy in and of itself—there is
little remaining justification for convicting the unimpaired
chronic recreational marijuana user simply for having a high
THC blood concentration. Chronic recreational users are akin to
medical marijuana patients; their THC concentration is not
necessarily indicative of impairment and may only be indicative of
prior use. Given that chronic marijuana smokers may use the
drug at similar levels as marijuana patients, it would seemingly
violate the Equal Protection Clause to provide one class of user
with an affirmative defense and not the other.221
Chronic recreational marijuana users should therefore be
afforded the same affirmative defense to a marijuana DUI as
their medical counterparts, even if such a defense will appear
inherently weaker. The chronic recreational marijuana user will
not be able to submit a medical marijuana ID, since they
assumedly will not have one. Such a user would not have a
prescribing doctor who could provide testimony regarding the
chronicity of the defendant’s use or the recommended dosage.
Instead, the chronic recreational user would have to rely on
expert testimony from doctors and scientists opining about the
given individual’s tolerance in light of the individual’s chronic
220
221

See U.S. CONST. amend. XIV.
See id.
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use. Yet, evidence to prove chronic use may be difficult to present.
It is hard to imagine a jury sympathetic to the recreational user
who puts friends on the witness stand to testify that the
defendant used marijuana frequently, and in sufficient quantities,
to build a certain level of tolerance. Given the rapidly changing
views of marijuana, however, particularly in states that sanction
recreational use, it is conceivable that such an affirmative defense
could become a powerful tool in time.
It is likely that the medical marijuana patient will almost
always elicit more sympathy from the jury when raising such an
affirmative defense than will the chronic recreational user.
Regardless, any legislative attempt to move away from specific
THC concentration thresholds and toward a more subjective test
based upon actual driving impairment—and not the mere
presence of certain marijuana compounds in the blood—will be a
step toward a more just and scientific approach to handling
marijuana DUIs. A marijuana DUI regime that relies on actual
driving impairment through use of police body and dashboard
cameras, that provides an affirmative defense to users, and that
does not create statutory THC thresholds based upon murky
science, would be an ideal regulatory scheme until more research
on marijuana’s impairing effects establishes otherwise.
CONCLUSION
The rapid increase in the number of states sanctioning
the use of medical or recreational marijuana has produced the
unique issue of how to best create and enforce marijuana DUIs in
a non-prohibitionist era. Without the moral condemnation that
could be used to justify a per se prohibition on THC or its
metabolites in the blood of drivers, a new statutory regime based
upon science is necessary to handle the influx of medical
marijuana patients and legal recreational users. Given the unique
characteristics of marijuana, and its vast degree of impairment
variability among individual users,222 a more scientific approach
would necessarily rely heavily on subjective driver impairment,
rather than objective THC blood concentrations that often
reveal little about a given driver’s actual level of impairment.223
To achieve this goal, it is necessary to provide legal marijuana
users with an affirmative defense to a marijuana DUI charge—
similar to that recognized by the Arizona Supreme Court in

222
223

See Sewell et al., supra note 44, at 188.
See Roth, supra note 16, at 890–91.
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Dobson under the AMMA.224 Statutory thresholds, such as
Colorado’s five-nanogram limit, sanctioning a legal blood
concentration of THC for drivers, fail by being underinclusive for
the novice marijuana user who may be too impaired to drive but
still remain under the legal THC threshold. States should thus
focus less on THC tests—which describe past marijuana use, but
do not correlate linearly with impairment225—and more on
actual driver impairment. This goal can be achieved by
expanding the use of DREs, police body cameras, and dashboard
cameras to corroborate evidence of actual driver impairment.
Finally, and perhaps most importantly, it is necessary
to increase research in the area of marijuana and its impairing
effects on drivers. Marijuana’s listing as a Schedule I drug
remains a major barrier to research in this rapidly evolving
field.226 Until marijuana is subject to the same type of decadeslong research that drunk driving was, legal marijuana users
should be afforded affirmative defenses to DUI charges, and
government resources should be focused on ways to criminalize
impaired drivers without prosecuting safe ones.
Zack G. Goldberg†

See Dobson v. McClennen, 361 P.3d 374, 378 (Ariz. 2015).
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